可溶性环氧化物水解酶抑制剂对心脑血管系统疾病的影响

神经药理学报 ›› 2012, Vol. 2 ›› Issue (5): 40-44.

可溶性环氧化物水解酶抑制剂对心脑血管系统疾病的影响

杨辉,谭晓虹

河北北方学院药学系，张家口，075000，中国

出版日期:2012-10-26 发布日期:2014-06-27
通讯作者: 谭晓虹，女，副教授，硕士；研究方向：神经药理学；Tel：+86-0313-4029306, E-mail: txhzbwzl@126.com
作者简介:杨辉，男，副教授，硕士；研究方向：心血管药物合成；E-mail: yangkcer@163.com

The Effects of Soluble Epoxide Hydrolase Inhibitors on Cardiovascular and Cerebrovascular System Disease

YANG Hui, TAN Xiao-hong

Department of Pharmacy, Hebei North University, Zhangjiakou, 075000, China

Online:2012-10-26 Published:2014-06-27
Contact: 谭晓虹，女，副教授，硕士；研究方向：神经药理学；Tel：+86-0313-4029306, E-mail: txhzbwzl@126.com
About author:杨辉，男，副教授，硕士；研究方向：心血管药物合成；E-mail: yangkcer@163.com

摘要/Abstract

摘要： 花生四烯酸（arachidonic acid，AA）可被细胞色素P450代谢为环氧花生四烯酸（epoxyeicosatrienoic acids，EETs）。后者具有促进血管生成，抑制炎症过程及血小板聚集等多种生理活性。EETs被可溶性环氧化物水解酶（solubleepoxidehydrolase，sEH）迅速降解，生物活性降低。因此，抑制sEH可作为治疗心脑血管疾病的靶点，本文就sEH抑制剂对高血压、动脉粥样硬化及缺血性脑卒中、心肌梗死、慢性心力衰竭等疾病的作用及机制做一综述.

关键词: 可溶性环氧化物水解酶抑制剂, 环氧花生四烯酸, 心脑血管疾病

Abstract: Arachidonic acid is metabolized to epoxyeicosatrienoic acids (EETs) by cytochrome P450 epoxygenase. EETspromote angiogenesis and
inhibit inflammatory processes and platelet aggregation. EETs are rapidly degradated by soluble epoxide hydrolase (sEH) and their biological activity decreased. Therefore, sEH may be used as a therapeutic target in hypertension, myocardial infarction, renal diseases and ischemic stroke. This review summarized the effects of sEH inhibitors on hypertension, atherosclerosis, cerebral ischemic stroke and chronic heart failure, and discussed the mechanisms of the effects.

Key words: solubleepoxidehydrolase inhibitors, epoxyeicosatrienoic acids（EETs）, cardiovascular and cerebrovascular system disease

杨辉, 谭晓虹. 可溶性环氧化物水解酶抑制剂对心脑血管系统疾病的影响 [J]. 神经药理学报, 2012, 2(5): 40-44.

YANG Hui, TAN Xiao-hong. The Effects of Soluble Epoxide Hydrolase Inhibitors on Cardiovascular and Cerebrovascular System Disease[J]. ACTA NEUROPHARMACOLOGICA, 2012, 2(5): 40-44.

参考文献

[1] Jeffrey J Lliff, Nabil J Alkayed. Soluble epoxide hydrolase inhibition: Targeting multiple mechanisms of ischemic brain injury with a single agent [J]. Fut Neurol, 2009, 4(2): 179-199.

[2] 王守宝，郭晶，祖勉，等. 人源可溶性环氧化物水解酶（hsEH）抑制剂高通量筛选模型建立及其应用[J].中国药理学通报，2009, 25（suppl）：122.

[3] William B Campbell, Debebe Gebremedhin, Phillip F Pratt, et al. Identification of epoxyeicosatrienoic acids as endothelium-derived hyperpolarizing factors [J]. Circ Res, 1996, 78(3): 415-423.

[4] J Vriens, G Owsianik, B Fisslthaler, et al. Modulation of the Ca2 permeable cation channel TRPV4 by cytochrome P450 epoxygenases in vascular endothelium [J]. Circ Res, 2005, 97(9): 908-915.

[5] Hantz C Hercule, Wolf-Hagen Schunck, Volkmar Gross, et al. Interaction between P450 eicosanoids and nitric oxide in the control of arterial tone in mice[J]. Arterioscler Thromb Vasc Biol, 2009, 29(1): 54-60.

[6] John D Imig, Zhao Xue-ying, Jorge H Capdevila, et al. Soluble epoxide hydrolase inhibition lowers arterial blood pressure in angiotensin II hypertension[J]. Hypertension, 2002, 39(2): 690-694.

[7] Zhao Xue-ying, Tatsuo Yamamoto, John W Newman, et al. Soluble epoxide hydrolase inhibition protects the kidney from hypertension-induced damage [J]. J Am Soc Nephrol, 2004, 15(5): 1244-1253.

[8] AI Ding, Fu Yi, Guo De-liang, et al. Angiotensin II up-regulates soluble epoxide hydrolase in vascular endothelium in vitro and in vivo[J]. Proc Natl Acad Sci USA, 2007, 104(21): 9018-9023.

[9] Yu Zhi-gang, Xu Feng-yun, Linn M Huse, et al. Soluble epoxide hydrolase regulates hydrolysis of vasoactive epoxyeicosatrienoic acids [J]. Circ Res, 2000, 87(11): 992-998.

[10] F Catella, J A Lawson, D J Fitzgerald, et al. Endogenous biosynthesis of arachidonic acid epoxides in humans: Increased formation in pregnancy-induced hypertension[J]. Proc Natl Acad Sci USA, 1990, 87(15): 5893-5897.

[11] Christopher J Sinal, Masaaki Miyata, Masahiro Tohkin, et al. Targeted disruption of soluble epoxide hydrolase reveals a role in blood pressure regulation [J]. J Biol Chem, 2000, 275(51): 40504-40510.

[12] Krairerk Athirakul, J Alyce Bradbury, Joan P Graves, et al. Increased blood pressure in mice lacking cytochrome P450 2J5 [J]. FASEB J, 2008, 22(12): 4096-4108.

[13] David Loch, Andrew Hoey, Christophe Morisseau, et al. Prevention of hypertension in DOCA-salt rats by an inhibitor of soluble epoxide hydrolase[J]. Cell Biochem Biophys, 2007, 47(1): 87-98.

[14] Oliver Jung, Ralf P Brandes, In-Hae Kim, et al. Soluble epoxide hydrolase is a main effector of angiotensin II-induced hypertension [J]. Hypertension, 2005, 45(4): 759-765.

[15] L I Jing, A C Mairead, N C Praveen, et al. Soluble epoxide hydrolase inhibitor, AUDA, prevents early salt-sensitive hypertension [J]. Frontiers in Bioscience, 2008, 13(3): 3480-3487.

[16] Marc Reverman, Eduardo Barbosa-Sicard , Eva Dony, et al. Inhibition of the soluble epoxide hydrolase attenuates monocrotaline-induced pulmonary hypertension in rats [J]. J Hypertens, 2009, 27(2): 322-331.

[17] William G Sanders, Christophe Morisseau, Bruce D Hammock, et al. Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-in?ammatory effects of a soluble epoxide hydrolase inhibitor [J].Am J Physiol Cell Physiol, 2012, 303(3):C278-C290.

[18] Kara R Schmelzer, Lukas Kubala, John W Newman, et al. Soluble epoxide hydrolase is a therapeutic target for acute inflammation[J]. Proc Natl Acad Sci USA, 2005, 102(28): 9772-9777.

[19] Kara R Schmelzer, Bora Inceoglu, Lukas Kubala, et al. Enhancement of antinociception by coadministration of nonsteroidal anti-inflammatory drugs and soluble epoxide hydrolase inhibitors[J]. Proc Natl Acad Sci, USA 2006, 103(37): 13646-13651.

[20] Alexis N. Simpkins, R. Daniel Rudic, Derek A Schreihofer, et al. Soluble epoxide inhibition is protective against cerebral ischemia via vascular and neural protection [J]. Am J Pathol, 2009, 174(6)：2086-2095

[21] Zhang Wen-ri, Takashi Otsuka, Nobuo Sugo，et al. Soluble epoxide hydrolase gene deletion is protective against experimental cerebral ischemia [J]. Stroke, 2008, 39(7): 2073-2078.

[22] Anne M Dorrance, Nicole Rupp, David M Pollock, et al. Epoxide hydrolase inhibitor, 12-(3-adamantan-1-yl-ureido)dodecanoic acid )(AUDA), reduces ischemic cerebral infarct size in stroke-prone spontaneously hypertensive rats [J]. J Cardiovasc Pharmacol, 2005, 46(6): 842–848.

[23] Li Ning, Liu Jun-yan, Valeriy Timofeyev, et al. Beneficial effects of soluble epoxide hydrolase inhibitors in myocardial infarction model: Insight gained using metabolomic approaches[J]. J Mol Cell Cardiol, 2009, 47(6)：835-845.

[24] Andrew R Kompa, Bing H Wang, Xu Guo-ying, et al. Soluble epoxide hydrolase inhibition exerts beneficial anti-remodeling actions post-myocardial infarction [J]. Int J Cardiol, 2013, 167(1)：210-219.

[25] Nassiba Merabet, Jeremy Bellien, Etienne Glevarec, et al. Soluble epoxide hydrolase inhibition improves myocardial perfusion and function in experimental heart failure [J]. J Mol Cell Cardiol, 2012, 52(3)：660–666.

[26] Ai Ding, Pang Wei, Li Nan, et al. Soluble epoxide hydrolase plays an essential role in angiotensin II-induced cardiac hypertrophy [J]. Proc Natl Acad Sci USA, 2009, 106(2): 564-569.

[27] Xu Dan-yan, Li Ning, He Yuxia, et al. Prevention and reversal of cardiac hypertrophy by soluble epoxide hydrolase inhibitors [J]. Proc Natl Acad Sci USA, 2006, 103(49): 18733-18738.

[28] Myriam Fornage, Cruz A Hinojos, Barbara W Nurowska, et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats [J]. Hypertension, 2002, 40(4): 485-490.

[29] M Fornage, Hinojos CA, Nurowska BW, et al. Polymorphism in soluble epoxide hydrolase and blood pressure in spontaneously hypertensive rats [J]. Hypertension, 2002, 40(4): 485-490.(重复)

[30] Myriam Fornage, Eric Boerwinkle, Peter A Doris, et al. Polymorphism of the soluble epoxide hydrolase is associated with coronary artery calcification in African-American subjects: The Coronary Artery Risk Development in Young Adults (CARDIA) study [J]. Circulation, 2004, 109(3): 335-339.

[31] Michael P Hutchens, Takaaki Nakano, Jennifer Dunlap, et al. Soluble epoxide hydrolase gene deletion reduces survival after cardiac arrest and cardiopulmonary resuscitation[J]. Resuscitation, 2008, 76(1): 89-94.

[32] Atsuko Motoki, Matthias J Merkel, William H Packwood, et al. Soluble epoxide hydrolase inhibition and gene deletion are protective against myocardial ischemia reperfusion injury in vivo[J]. Am J Physiol Heart Circ Physiol, 2008, 295(5): H2128- H2134.

[33] John M Seubert, Christopher J Sinal, Joan Graves, et al. Role of soluble epoxide hydrolase in postischemic recovery of heart contractile function [J]. Circ Res, 2006, 99(4): 442-450.

[34] ClinicalTrial Gov. Evaluation of soluble epoxide hydrolase (s-EH) inhibitor in patients with mild to moderate hypertension and impaired glucose tolerance [EB/OL]. http://www.clinicaltrials.gov/ct2/show/NCT00847899?term=NCT00847899&rank=1.

[35] Benjamin B Davis, Christophe Morisseau, John W Newman, et al. Attenuation of vascular smooth muscle cell proliferation by 1-cyclohexyl-3-dodecyl urea is independent of soluble epoxide hydrolase inhibition[J]. J Pharmacol Exp Ther, 2006, 316(2): 815-821.